Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.51 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.46 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | F3 | P13726 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.44 |
| ▸ | PYGL | P06737 | 1/20 | 0.43 |
| ▸ | PYGM | P11217 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1609672 | 0.87 | SMAD3 (0.60) | CYP19A1PIN1SMAD3KDM4EHPGD | |
| SCHEMBL1615613 | 0.83 | CYP19A1 (0.49) | CYP19A1PIN1SMAD3KDM4EHPGD | |
| SCHEMBL5476861 | 0.82 | PYGL (0.45) | CYP19A1PIN1ALDH1A1TSHRIMPDH2 | |
| Alcohol SCHEMBL27477859 | 0.81 | KDM4E (0.55) | CYP19A1PIN1SMAD3KDM4EHPGD | |
| SCHEMBL1616056 | 0.79 | XDH (0.56) | CYP19A1PIN1KDM4EHPGDHSD17B10 | |
| SCHEMBL25812304 | 0.79 | PYGL (0.52) | CYP19A1PIN1KDM4EALDH1A1IMPDH2 | |
| SCHEMBL31069438 | 0.79 | XDH (0.56) | CYP19A1PIN1KDM4EHPGDHSD17B10 | |
| SCHEMBL10066185 | 0.76 | CYP19A1 (0.49) | CYP19A1PIN1IMPDH2IMPDH1PYGL | |
| SCHEMBL24019976 | 0.76 | ALOX15 (0.54) | CYP19A1KDM4EALDH1A1PYGLPYGM | |
| SCHEMBL1420412 | 0.76 | KDM4E (0.68) | KDM4EHPGDHSD17B10ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105851-A1 | Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-10 | — | — | US | disclosed |
| EP-1687313-A1 | INDOLYL-THIEN 3,4-B]PYRAZIN-3-ONE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Pharmaceuticals Corporation (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20060004011-A1 | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-01-05 | — | — | US | disclosed |
| EP-1565455-A1 | INDOLYL PYRAZINONE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | Bayer Pharmaceuticals Corporation (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2005051957-A1 | INDOLYL-THIENO`3,4-B!PYRAZIN-3-ONE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2004043950-A1 | INDOLYL PYRAZINONE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105851-A1 | Indolyl-thienopyrazinone derivatives useful for treating hyperproliferative disorders and diseases associated with angiogenesis | MKI67, CDK4, PGF | CYP19A1 287/4885PIN1 522/4885SMAD3 1982/4885 |
| US-20060004011-A1 | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | MKI67, VEGFA, FLT1 | CYP19A1 243/4885PIN1 570/4885SMAD3 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.